Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.54 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.54 |
| ▸ | HTR1A known ✓ | P08908 | 3/20 | 0.51 |
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.51 |
| ▸ | SLC6A4 known ✓ | P31645 | 3/20 | 0.51 |
| ▸ | SLC6A3 known ✓ | Q01959 | 3/20 | 0.51 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.49 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.49 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.49 |
| ▸ | HTR6 | P50406 | 3/20 | 0.54 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.54 |
| ▸ | HTR3B | O95264 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
| ▸ | HTR3A | P46098 | 1/20 | 0.54 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.54 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL7650493 | 1.00 | HTR6 (0.54) | HTR6HTR3EHTR3BADRB1DRD2 | |
| Fumaric Acid SCHEMBL3873156 | 1.00 | HTR6 (0.54) | HTR6HTR3EHTR3BADRB1DRD2 | |
| Fumaric Acid SCHEMBL7648541 | 1.00 | HTR6 (0.54) | HTR6HTR3EHTR3BADRB1DRD2 | |
| SCHEMBL3867980 | 0.88 | HTR6 (0.68) | HTR6HTR3EHTR3BADRB1DRD2 | |
| SCHEMBL3951002 | 0.88 | HTR6 (0.68) | HTR6HTR3EHTR3BADRB1DRD2 | |
| SCHEMBL30159754 | 0.88 | HTR6 (0.68) | HTR6HTR3EHTR3BADRB1DRD2 | |
| Hydrochloric Acid SCHEMBL4519236 | 0.86 | LMNA (0.69) | HTR6HTR3EHTR3BADRB1DRD2 | |
| SCHEMBL14984402 | 0.82 | HTR6 (0.60) | HTR6HTR3EHTR3BADRB1DRD2 | |
| Ethylamine SCHEMBL7690866 | 0.81 | HTR6 (0.59) | HTR6HTR3EHTR3BADRB1DRD2 | |
| Hydrochloric Acid SCHEMBL246152 | 0.81 | LMNA (0.61) | HTR6HTR3EHTR3BADRB1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517885-B2 | Substituted [4-(4-phenyl-piperazin-1-yl)-cyclohexyl]-urea compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-14 | — | — | US | disclosed |
| US-7459557-B2 | Substituted isoindole-1,3-diones | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-12-02 | — | — | US | disclosed |
| US-20070123542-A1 | Substituted [4-(4-phenyl-piperazin-1-yl)-cyclohexyl]-urea compounds | CHIU GEORGE | 2007-05-31 | — | — | US | disclosed |
| US-20070093500-A1 | Substituted isoindole-1,3-diones | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123542-A1 | Substituted [4-(4-phenyl-piperazin-1-yl)-cyclohexyl]-urea compounds | ADRA1D, ADRA1A, ADRB1 | ADRB1 3/4885DRD2 662/4885HTR1A 30/4885 |
| US-20070093500-A1 | Substituted isoindole-1,3-diones | ADRA1D, ADRA1A, ADRB1 | ADRB1 3/4885DRD2 94/4885HTR1A 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.